nach oben

Erschienen in:

01.02.2023 | Media release

Safety concern for levothyroxine-containing products: biotin interference with thyroid immunoassays

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

A safety notice for levothyroxine-containing products and the risk of biotin interference with thyroid immunoassays has been issued by the Health Products Regulatory Authority (HPRA) in Ireland in a direct healthcare professional communication (DHPC). …

Levothyroxine containing products - Important Safety Information from Amdipharm Limited Ireland and Teva Pharmaceuticals Ireland as approved by the HPRA (20.01.23). Internet Document : 20 Jan 2023. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/levothyroxine-containing-products---important-safety-information-from-amdipharm-limited-ireland-and-teva-pharmaceuticals-ireland-as-approved-by-the-hpra-(20.01.23)&id=adb21326-9782-6eee-9b55-ff00008c97d0

Titel: Safety concern for levothyroxine-containing products: biotin interference with thyroid immunoassays
Publikationsdatum: 01.02.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-32892-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Safety concern for levothyroxine-containing products: biotin interference with thyroid immunoassays

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Paracetamol

Cefazolin/clindamycin

Dexamethasone

Immune checkpoint inhibitors: significant risk of hepatotoxicity

Azacitidine

Multiple drugs